REMINDER: Our focusIR Investor Webinar takes place TONIGHT with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Regulatory News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Final Award of NF Mark

27 Feb 2013 08:39

RNS Number : 7711Y
Akers Biosciences, Inc.
27 February 2013
 



27 February 2013

 

 

Akers Biosciences, Inc.

("ABI" or the "Company")

 

French Certification for Disposable Breath Alcohol Detectors Received 

 

 

ABI, a leading designer and manufacturer of rapid diagnostic screening and testing products, is pleased to announce that further to the Company's announcement on 19 February 2013, ABI's proprietary disposable breath alcohol detectors have been granted the final award of the NF Marque ("NF Mark") number 18/01. The NF Mark enables the breathalysers be marketed and sold to consumers in and around France under the brand name CHUBE by ABI's UK based partner (en)10 (Global) Limited. This follows the Company's breath alcohol detector being deemed in compliance with the quality criteria defined in French Standard NF X 20-702 for disposable breathalysers by the national reference laboratory of France, Laboratoire National de Métrologie et d'Essais under Certificate 25024.

 

Thomas A. Nicolette, Chief Executive Officer of ABI, commented: "We are honored that our detector has been certified against the French Standard and are delighted that it now bears the prestigious NF Mark. Over the last ten months (en)10  and ABI have collaborated to develop a specific product for the French market that offers 100% accuracy and reliability. Inappropriate alcohol consumption isn't just a problem on the roads, it's a major public health issue worldwide. The current breathalyzer law in France is an opportunity to bring fresh thinking and a new product to the market that can help consumers to improved well-being by encouraging sustainable changes in their attitudes to alcohol consumption. Using CHUBE, with proven change programmes and modern consumer marketing, means a highly precise disposable, single use device is now available to the French consumer at a low enough price to encourage repeat use"

 

Enquiries:

 

Thomas A. Nicolette

President and CEO

Tel. +1 856 848 8698

 

Antony Legge or James Thomas

Daniel Stewart & Company plc (Nomad and Broker)

Tel. +44 (0)20 7776 6550

 

 

About Akers Biosciences, Inc

Akers Biosciences develops, manufactures, and supplies rapid, point-of-care screening and testing products designed to bring health status information, both rapidly and directly, to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere, in minutes, since time is always of essence. ABI is aligned with high volume medical product distributors to help facilitate the Company's growth into a major, worldwide competitor in the field of rapid diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com

 

About (en)10 (Global) Ltd

Combining leading science innovations and clever design, (en)10 provides people the means to affect simple, precise, low-cost alcohol screening and the thinking, programmes and products to encourage broader, positive changes in attitudes to responsible alcohol consumption. It provides a fresh approach to achieving a healthy work culture and a more productive business: cutting costs and improving lives.  Additional information on the Company and its products can be found at www.en-10.com and at www.soyezchube.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAPAXADPDEEF
Date   Source Headline
14th Jul 20177:00 amRNSNotice of AGM & Directorate Changes
3rd Jul 20172:53 pmRNSForm S-3 Registration Statement
9th Jun 20174:51 pmRNSIssue of Equity
16th May 20177:00 amRNS1st Quarter Results
12th May 20172:30 pmRNSNotice of Q1 Results
5th May 201710:53 amRNSIssue of Equity
24th Apr 20175:12 pmRNSIssue of Equity
11th Apr 20179:13 amRNSHolding(s) in Company
11th Apr 20177:00 amRNSFinal Results
10th Apr 20173:00 pmRNSNotice of Results
10th Apr 201712:00 pmRNSIssue of Equity
10th Apr 20177:00 amRNSHeparin PF4 Rapid Test in Puerto Rico
6th Apr 20175:39 pmRNSIssue of Equity
4th Apr 20174:18 pmRNSIssue of Equity
31st Mar 20177:00 amRNSIssue of Equity
30th Mar 20171:30 pmRNSDetailed Year-end Trading Update
29th Mar 20177:00 amRNSNotice of Results
28th Mar 201712:00 pmRNSInitial Order for Rapid Cholesterol Self-test
16th Feb 20177:00 amRNSUS Patent for Akers Wellness Tests Cartridge
1st Feb 20177:00 amRNSTrading Update
13th Jan 20177:00 amRNSIssue of Equity
10th Jan 20177:00 amRNSIssue of Equity
9th Jan 20177:00 amRNSSupplement to Form S-3 Registration Statement
19th Dec 20165:00 pmRNSResult of AGM
19th Dec 20167:00 amRNSAgreement with GNYHA for PIFA Heparin PF4 Test
1st Dec 201612:00 pmRNSUS Distribution Agreement: Cholesterol Self-test
28th Nov 20167:06 amRNSClinical Trial for BreathScan DKA Completed
17th Nov 20167:00 amRNSSupplement to Form S-3 Registration Statement
14th Nov 201612:00 pmRNSNotice of AGM
14th Nov 20167:00 amRNS3rd Quarter Results
10th Nov 20167:00 amRNSEuropean Patent Granted
9th Nov 20164:29 pmRNSNotice of Q3 Results
25th Oct 20167:00 amRNSFiling of Form S-3 Registration Statement
19th Aug 20167:00 amRNSSettlement of Dispute with ChubeWorkx
18th Aug 20167:00 amRNSResults of OxiChek Test Study
11th Aug 20167:00 amRNSHalf Yearly Results
9th Aug 20164:00 pmRNSNotice of H1 2016 Earnings
30th Jun 20167:00 amRNSClinical Trial for Rapid Chlamydia Test Completed
27th Jun 20167:00 amRNSDistribution Agreement for BreathScan OxiChekT
14th Jun 201612:00 pmRNSIssue of Equity & PDMR Shareholding
26th May 20165:10 pmRNSPDMR Shareholding
12th May 20167:00 amRNSFinancial Results for Q1 2016
10th May 201612:00 pmRNSNotice of Q1 Results
25th Apr 201612:00 pmRNSBoard Rearrangement
30th Mar 20167:00 amRNSFinal Results
23rd Mar 20167:00 amRNSUS Patent - Heparin/PF4 Antibody Detection
16th Mar 20167:00 amRNSNotice of Results
2nd Mar 20167:00 amRNS$2.5M Product Order
29th Feb 20167:00 amRNSSenior Commercial Team Appointments
6th Jan 20167:00 amRNSDirectors Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.